Shattuck Labs, Inc. (STTK)
NASDAQ: STTK · Real-Time Price · USD
5.54
+0.05 (0.91%)
At close: Oct 26, 2026, 4:00 PM EDT
5.80
+0.26 (4.69%)
Pre-market: Oct 27, 2026, 5:20 AM EDT
Shattuck Labs Revenue
Shattuck Labs had revenue of $1.00M in the twelve months ending June 30, 2026, down -66.63% year-over-year. In the year 2025, Shattuck Labs had annual revenue of $1.00M, down -82.52%. That makes Shattuck Labs the 43,619th largest company in the world by revenue and 6,103rd in the United States.
Revenue (ttm)
$1.00M
Revenue Growth
-66.63%
P/S Ratio
556.01
Revenue / Employee
$25,000
Employees
40
Market Cap
556.01M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.00M | -4.72M | -82.52% |
| Dec 31, 2024 | 5.72M | 4.06M | 245.26% |
| Dec 31, 2023 | 1.66M | 1.01M | 154.14% |
| Dec 31, 2022 | 652.00K | -29.37M | -97.83% |
| Dec 31, 2021 | 30.02M | 20.08M | 202.16% |
| Dec 31, 2020 | 9.93M | 47.00K | 0.48% |
| Dec 31, 2019 | 9.89M | -12.56M | -55.94% |
| Dec 31, 2018 | 22.44M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| MiMedx Group | 355.17M |
| Puma Biotechnology | 231.24M |
| Zevra Therapeutics | 136.07M |
| 4D Molecular Therapeutics | 92.01M |
| Crescent Biopharma | 11.88M |
| Aclaris Therapeutics | 8.22M |
| DBV Technologies | 5.04M |
STTK News
- 13 days ago - Shattuck Labs Announces Two Poster Presentations at UEG Week 2026 - GlobeNewsWire
- 15 days ago - Shattuck Labs initiated with a Buy at UBS - TheFly
- 24 days ago - Shattuck Labs price target raised to $14 from $11 at Wedbush - TheFly
- 24 days ago - Shattuck Labs price target raised to $19 from $17 at Needham - TheFly
- 25 days ago - Shattuck Labs Slides: Corporate presentation - Filings
- 25 days ago - Shattuck Labs to evaluate SL-325 in Phase 2 trial, appoints Ravichandran as SVP - TheFly
- 25 days ago - Shattuck Labs Announces Phase 2 Clinical Trial of SL-325 in Hidradenitis Suppurativa and Appointment of Shoba Ravichandran, M.D., as Senior Vice President, Clinical Development - GlobeNewsWire
- 26 days ago - Shattuck Labs has positive readthrough from Merck data, says H.C. Wainwright - TheFly